# Optimi Health (OPTH) — News

OPTH · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/opth/news

## Recent headlines

- [Optimi Health completes psilocybin production for Health Canada-approved phase 2 MDD trial and commercial TRD supply](https://www.ainvest.com/news/optimi-health-completes-psilocybin-production-health-canada-approved-phase-2-mdd-trial-commercial-trd-supply-2609) — AInvest Wire, Sep 23, 2026
- [Optimi Health appoints Dr. Michael Blough as chief clinical development officer](https://www.ainvest.com/news/optimi-health-appoints-dr-michael-blough-chief-clinical-development-officer-2609) — AInvest Wire, Sep 22, 2026
  Optimi Health Corp. (OPTH) has announced the appointment of Dr. Michael Blough as Chief Clinical Development Officer, effective immediately. In this role, Dr. Blough will oversee the development and execution of clinical protocols for the company’s therapeutic products, including GMP-certified MDMA…
- [Optimi Health Corp - Primary endpoint is change in CAPS-5 PTSD scale](https://www.ainvest.com/news/optimi-health-corp-primary-endpoint-change-caps-5-ptsd-scale-2609) — AInvest Wire, Sep 16, 2026
- [Optimi Health expands clinical program with phase 3 trial evaluating MDMA-assisted therapy for post-traumatic stress disorder](https://www.ainvest.com/news/optimi-health-expands-clinical-program-phase-3-trial-evaluating-mdma-assisted-therapy-post-traumatic-stress-disorder-2609) — AInvest Wire, Sep 16, 2026
  Optimi Health Corp. has announced the initiation of a Phase 3 clinical trial to evaluate the efficacy and safety of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), marking a significant expansion of the company’s clinical program. The trial follows recent regulatory developments,…
- [Optimi Health Corp - Trial initiation planned for H1 2027, dosing to complete by end of 2027](https://www.ainvest.com/news/optimi-health-corp-trial-initiation-planned-h1-2027-dosing-complete-2027-2609) — AInvest Wire, Sep 10, 2026
  Optimi Health Corp has announced plans to initiate a clinical trial in the first half of 2027, with dosing expected to be completed by the end of the year, according to a recent company statement. The trial is part of the company’s ongoing research and development efforts in the healthcare sector.…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).